Search
-
High-purchase cost and convenience of charging logistics remains barriers to owning an EV for Americans
Ipsos polling finds that some non-EV owning Americans are nudged towards considering an EV by improved charging infrastructure and government subsidies
-
Most Americans still think Trump should go to trial before the 2024 Presidential election
Meanwhile, partisanship divides Americans when it comes to believing whether Donald Trump is guilty of a number of alleged crimes
-
Wellness
Emerging technologies and changing perspectives could help Americans live longer and healthier lives. Here’s what that could look like — and what it’ll mean for brands and businesses.
-
Shifts: Three forces that will shape the future of wellness
Ipsos Strategy3’s Trevor Sudano looks at the forces that could transform health and wealth in America, from rising temperatures to rising medical bills.
-
Future Jobs to Be Done
Ipsos Strategy3’s Mercedes Bender considers the products and services people will need to optimize their health in a changing world.
-
Ipsos Reputation Council 2024: AI, Sponsorships and More
Hear new findings and practical guidance to assist corporate communicators with diagnosing and proactively managing risk to maximize business outcomes in the year ahead.
-
Millennials and Gen Z less in favor of gender equality than older generations
Ipsos’ annual International Women’s Day finds 60% of Gen Z men across 31 countries think women’s equality discriminates against men.
-
New research suggests that concerns about threats to democracy match the economy and immigration as issues shaping the 2024 election
Ipsos poll finds that negative partisanship is the main issue concern for two in five Americans
-
Ipsos Update – March 2024
Populism, UX, Love… Ipsos Update explores the latest research & thinking on key topics from Ipsos teams around the world.
-
Understanding Patients with Metastatic Breast Cancer – A Preference for Oral Treatments
Research conducted by Ipsos in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company explores the time commitment and treatment preferences among women living with ER+, HER2- metastatic breast cancer